CytoDyn (CYDY) Shares Outstanding (2010 - 2026)
CytoDyn's (CYDY) quarterly Shares Outstanding (Entity) came in at $1.4 billion in Q1 2026, up 10.19% YoY from $1.2 billion in Q1 2025, and up 7.27% on a QoQ basis from $1.3 billion in Q4 2025.
CytoDyn (CYDY) Shares Outstanding (2010 - 2026) Analysis & Trends
CytoDyn (CYDY) has 17 years of Shares Outstanding (Entity) data on file, last reported at $1.4 billion in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 10.19% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $1.4 billion (up 10.19% YoY) and the FY2025 annual result came in at $1.2 billion, up 17.98% from the prior year.
- Shares Outstanding (Entity) advanced to $1.4 billion in Q1 2026, from $1.3 billion in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $1.4 billion in Q1 2026 to a low of $695614.0 in Q1 2022.
- A 5-year average of $992.6 million and a median of $990.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) sank 99.89% — and 2023, when it surged 120229.81%.
- Tracing CYDY's Shares Outstanding (Entity) over 5 years: stood at $825.3 million in 2022, then grew by 17.69% to $971.3 million in 2023, then increased by 25.97% to $1.2 billion in 2024, then climbed by 3.48% to $1.3 billion in 2025, then grew by 7.27% to $1.4 billion in 2026.
- The last three Shares Outstanding (Entity) figures came in at $1.4 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | 1.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 1.28 Bn |
| Nov 30, 2025 | 1.26 Bn |
| Aug 31, 2025 | 1.25 Bn |
| May 31, 2025 | 1.21 Bn |
| Feb 28, 2025 | 1.23 Bn |
| Nov 30, 2024 | 1.22 Bn |
| Aug 31, 2024 | 1.14 Bn |
| May 31, 2024 | 969.51 Mn |
| Feb 29, 2024 | 982.21 Mn |
| Nov 30, 2023 | 958.99 Mn |
| Aug 31, 2023 | 923.59 Mn |
| May 31, 2023 | 836.53 Mn |
| Feb 28, 2023 | 832.22 Mn |
| Nov 30, 2022 | 813.37 Mn |
| Aug 31, 2022 | 787.86 Mn |
| May 31, 2022 | 676.90 Mn |
| Feb 28, 2022 | 695,614.00 |
| Nov 30, 2021 | 662.60 Mn |
| Aug 31, 2021 | 632.60 Mn |
| May 31, 2021 | 587.59 Mn |